The Netherlands is experiencing a surge in poisonings linked to the unsupervised use of slimming medications, according to the toxicological center NVIC. This year alone, the center has already received 105 reports, a significant increase compared to 75 in all of 2024 and just 41 in 2023.

Most reported cases involve semaglutide, the active ingredient found in drugs like Ozempic, Wegovy, and Rybelsus. Individuals are purchasing these medications online without medical guidance. The NVIC warns that the actual number of cases is likely higher, as many go unreported.

Symptoms of poisoning include nausea, vomiting, and gastrointestinal issues. In severe cases, individuals have experienced acute dehydration requiring emergency treatment. Overuse can also lead to gastroparesis, a condition affecting stomach muscle function and food processing.

Dylan de Lange, head of the NVIC, emphasizes the importance of gradual dosage increases under medical supervision. The rising popularity of these medications has prompted further research into rare but serious side effects, including acute kidney failure, liver infections, muscle wasting, and eye blood vessel infections that could cause blindness.

In 2024, approximately 120,000 people in the Netherlands were prescribed slimming drugs. Currently, insurance coverage for these medications is limited to individuals with a BMI of 35 or higher and type II diabetes. Despite this, a government survey revealed that 90% of respondents believe weight-loss drugs should be included in the basic insurance package.